Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa
Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa
复制标题
DOI：
10.1016/j.siny.2020.101182
复制
发表时间：
2020-12-01
影响因子：
3
通讯作者：
Ezeaka, Chinyere, V
中科院分区：
文献类型：
--
作者：
Ekhaguere, Osayame A.;Ayede, Adejumoke, I;Ezeaka, Chinyere, V
咖啡因是治疗早产儿呼吸暂停的首选药物。人们对撒哈拉以南非洲（SSA）低收入和中等收入国家咖啡因的可用性和可负担性知之甚少。我们在2020年对SSA的新生儿医生进行了一项在线调查，以确定他们获得咖啡因的机会。在90名受邀参与者中，55人做出了回应（61%）。他们在13个撒南非洲国家和48家医院工作。咖啡因在6个国家使用。其中5个国家报告了咖啡因的价格，从加纳的每3毫升1.73美元到肯尼亚的每3毫升73.63美元不等。最常见的主要障碍是药品价格高和缺乏可供购买的药品。一些受访者认为，其他甲基黄嘌呤是咖啡因的适当替代品。53名受访者中只有31人（58%）知道咖啡因被列入世界卫生组织（WHO）的基本药物清单。
Caffeine is the preferred pharmacologic treatment for apnea of prematurity. Little is known about the availability and affordability of caffeine in the low and middle-income countries of sub-Saharan Africa (SSA). We conducted an online survey in 2020 of newborn physicians in SSA to determine their access to caffeine. Of 90 invited participants, 55 responded (61%). They worked in 13 SSA countries and 48 hospitals. Caffeine was used in 6 countries. In 5 of these countries, the price of caffeine was reported and ranged from US $1.73 in Ghana to US $73.63 in Kenya per 3 mL vial. High drug prices and lack of drug availability for purchase were identified most frequently as primary barriers. Some respondents believed that other methylxanthines are adequate substitutes for caffeine. Only 31 of 53 (58%) respondents knew that caffeine is included in the essential drug list of the World Health Organization (WHO).